Pfizer announced the planned leadership and organizational structure for its research and commercial operations that will become effective when the Wyeth acquisition closes. The company will establish a research model designed to “advance the scientific capabilities of both Pfizer and Wyeth and to support the new company’s nine health care businesses,” according to a company statement. At the senior-most level of the organization, Pfizer will retain eight senior executives from Wyeth. Pfizer ...